Recent clinical trials indicate that current anti-angiogenic treatment targeting VEGF/VEGFR alone or in combination with chemotherapy cannot provide a survival advantage for breast cancer patients, which may be attributed to the feedback activation of non-VEGF angiogenic pathways [6, 11, 46]. The gene discussed is KDR; the disease is breast cancer.